• Sales revenue up 45.7% to $4.8 billion
• Normalised EBIT increased 183.5% to $68 million
• Net loss after tax of $12.9 million due to one-off merger costs

Sigma Healthcare Limited has reported its full year financial results for the year ended 31 January 2025. The company reported a 45.7% increase in sales revenue to $4.8 billion, up from $3.3 billion in the prior year. Normalised EBIT increased 183.5% to $68 million, however statutory EBIT declined 6.7% to $21.7 million due to one-off merger and integration costs. The company reported a net loss after tax of $12.9 million, compared to a profit of $5.3 million in the previous year. The loss was primarily attributable to the one-off costs associated with the merger. Net tangible assets per share decreased 4.1% to 44.8 cents. The company did not declare a final dividend for the year, with the focus on the merger integration. Sigma also announced changes to its board of directors, with the resignation of Kate Spargo and the appointment of Jack Gance, Mario Verrocchi, Damien Gance and Danielle Di Pilla, all from the Chemist Warehouse group.